|
2012 Conference Publication TOPGEAR: An international randomized phase III trial of preoperative chemoradiotherapy versus preoperative chemotherapy for resectable gastric cancer (AGITG/TROG/EORTC/NCIC CTG)Leong, Trevor, Smithers, Mark, Michael, Michael, Gebski, Val, Boussioutas, Alex, Miller, Danielle, Zalcberg, John Raymond, Wong, Rebecca and Haustermans, Karin (2012). TOPGEAR: An international randomized phase III trial of preoperative chemoradiotherapy versus preoperative chemotherapy for resectable gastric cancer (AGITG/TROG/EORTC/NCIC CTG). 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago Il, Jun 01-06, 2012. ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. |
|
2012 Conference Publication Long-term cure after complete resection and adjuvant immunotherapy for distant melanoma metastasesMorton, Donald L., Mozzillo, Nicola, Kashani-Sabet, Mohammed, Thompson, John F., Kelley, Mark C., De Conti, Ronald C., Lee, Jeffrey Edwin, Huth, James F., Faries, Mark B., Dalgleish, Angus George, Wagner, Jeffrey D., Hersh, Evan, Schneebaum, Schlomo, Anderson, Clay M., Smithers, Mark, Schuchter, Lynn Mara, McMasters, Kelly M., Testori, Alessandro, Karakousis, C. P. and Elashoff, Robert (2012). Long-term cure after complete resection and adjuvant immunotherapy for distant melanoma metastases. 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago Il, Jun 01-06, 2012. ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. |
|
2012 Journal Article Predictors of survival among patients diagnosed with adenocarcinoma of the esophagus and gastroesophageal junctionThrift, Aaron P., Nagle, Christina M., Fahey, Paul P., Smithers, Bernard M., Watson, David I. and Whiteman, David C. (2012). Predictors of survival among patients diagnosed with adenocarcinoma of the esophagus and gastroesophageal junction. Cancer Causes and Control, 23 (4), 555-564. doi: 10.1007/s10552-012-9913-1 |
|
2012 Conference Publication DOCTOR: A randomized phase II trial of preoperative cisplatin, 5-fluorouracil, and docetaxel with or without radiotherapy based on poor early response to standard chemotherapy for resectable adenocarcinoma of the esophagus and/or OG junctionBarbour, Andrew, Smithers, Bernard Mark, Burmeister, Bryan, Zalcberg, John Raymond, Spry, Nigel, Smith, Garrett, Wilson, Kate, Roff, Kate, Yip, Sonia and Walpole, Euan Thomas (2012). DOCTOR: A randomized phase II trial of preoperative cisplatin, 5-fluorouracil, and docetaxel with or without radiotherapy based on poor early response to standard chemotherapy for resectable adenocarcinoma of the esophagus and/or OG junction. 48th Annual Meeting of the American Society of Clinical Oncology (ASCO), Chicago, Il United States, 01-06 June 2012. Alexandria, VA United States: American Society of Clinical Oncology. |
|
2012 Conference Publication Immuno-chemoablation of metastatic melanoma with intralesional Rose BengalAgarwala, S. S., Thompson, J. F., Smithers, B. M., Ross, M., Coventry, B. J., Minor, D. R., Scoggins, C. R. and Wachter, E. (2012). Immuno-chemoablation of metastatic melanoma with intralesional Rose Bengal. 37th Congress of the European Society for Medical Oncology (ESMO), Vienna Austria, 28 September-02 October 2012. Oxford, United Kingdom: Oxford University Press. doi: 10.1093/annonc/mds404 |
|
2012 Journal Article The influence of pre-diagnostic demographic and lifestyle factors on oesophageal squamous cell carcinoma survivalThrift, Aaron P., Nagle, Christina M., Fahey, Paul P., Russell, Anne, Smithers, Bernard M., Watson, David I., Whiteman, David C. and for the Australian Cancer Study Clinical Follow-Up Study (2012). The influence of pre-diagnostic demographic and lifestyle factors on oesophageal squamous cell carcinoma survival. International Journal of Cancer, Early online (5), 1-29. doi: 10.1002/ijc.27420 |
|
2012 Conference Publication Activation of stat5 is an indicator of good prognosis in stage Ib and II melanomasRodero, M., Wright, A., Malt, M., Smithers, M., Green, A. and Khosrotehrani, K. (2012). Activation of stat5 is an indicator of good prognosis in stage Ib and II melanomas. The Australasian College of Dermatologists 45th Annual Scientific Meeting, Brisbane, QLD, Australia, 20-23 May 2012. Richmond, VIC, Australia: Wiley-Blackwell Publishing Asia. doi: 10.1111/j.1440-0960.2012.00892.x |
|
2012 Conference Publication MAGE-A3 expression in patients screened for the DERMA trial: a phase III trial testing MAGE-A3 immunotherapeutic in the adjuvant setting for stage IIIB-C-Tx melanomaThompson, John F., Santinami, Mario, Jouary, Thomas, Levchenko, Eugeny, Smithers, Bernard Mark, Mortier, Laurent, Grob, Jean Jacques, Trefzer, Uwe, Gutzmer, Ralf, Jamoul, Corinne, Peeters, Olivier, Dreno, Brigitte and Kirkwood, John M. (2012). MAGE-A3 expression in patients screened for the DERMA trial: a phase III trial testing MAGE-A3 immunotherapeutic in the adjuvant setting for stage IIIB-C-Tx melanoma. 48th Annual Meeting of the American Society of Clinical Oncology (ASCO), Chicago, Illinois, 1-6 June 2012 . Alexandria, VA, United States : American Society of Clinical Oncology. |
|
2012 Conference Publication Gene expression analysis of EAC in association with PET response.Wayte, Nicola, Nancarrow, Derek, Walpole, Euan Thomas, Lampe, Guy, Gotley, David, Smithers, Bernard Mark and Barbour, Andrew (2012). Gene expression analysis of EAC in association with PET response.. ASCO GI Symposium, San Diego, California, 24 January 2012. Alexandria, VA, United States: American Society of Clinical Oncology. doi: 10.1200/jco.2012.30.4_suppl.50 |
|
2012 Conference Publication Melanoma brain metastases: the impact of nodal diseaseJackson, J., Burmeister, B. H., Burmeister, E., Foote, M. C., Thomas, J. M. and Smithers, B. M. (2012). Melanoma brain metastases: the impact of nodal disease. 54th Annual Meeting of the American Society for Radiation Oncology (ASTRO), Boston, MA United States, 28-31 October 2012. Philadelphia, PA United States: Elsevier. doi: 10.1016/j.ijrobp.2012.07.1748 |
|
2011 Journal Article Local therapies and resection in Barrett's oesophagus and early oesophagogastric cancerTan, Alyisha, Macrae, Finlay and Smithers B. Mark (2011). Local therapies and resection in Barrett's oesophagus and early oesophagogastric cancer. Cancer Forum, 35 (3), 141-145. |
|
2011 Journal Article Whole genome expression array profiling highlights differences in mucosal defense genes in barrett's esophagus and esophageal adenocarcinomaNancarrow, Derek J., Clouston, Andrew D., Smithers, B. Mark, Gotley, David C., Drew, Paul A., Watson, David I., Tyagi, Sonika, Hayward, Nicholas K. and Whiteman, David C. (2011). Whole genome expression array profiling highlights differences in mucosal defense genes in barrett's esophagus and esophageal adenocarcinoma. Plos One, 6 (7) e22513, e22513-1-e22513-15. doi: 10.1371/journal.pone.0022513 |
|
2011 Journal Article Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysisSjoquist, Katrin M., Burmeister, Bryan H., Smithers, B. Mark, Zalcberg, John R., Simes, R. John, Barbour, Andrew, Gebski, Val and for the Australasian Gastro-Intestinal Trials Group (2011). Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncology, 12 (7), 681-692. doi: 10.1016/S1470-2045(11)70142-5 |
|
2011 Journal Article Defining cure for esophageal cancer: Analysis of actual 5-year survivors following esophagectomyHirst, Jodi, Smithers, Bernard Mark, Gotley, David C., Thomas, Janine and Barbour, Andrew (2011). Defining cure for esophageal cancer: Analysis of actual 5-year survivors following esophagectomy. Annals of Surgical Oncology, 18 (6), 1766-1774. doi: 10.1245/s10434-010-1508-z |
|
2011 Journal Article Trends in melanoma incidence among children: Possible influence of sun-protection programsBaade, Peter D., Green, Adele C., Smithers, Bernard Mark and Aitken, Joanne F. (2011). Trends in melanoma incidence among children: Possible influence of sun-protection programs. Expert Review of Anticancer Therapy, 11 (5), 661-664. doi: 10.1586/ERA.11.28 |
|
2011 Conference Publication Dermoscopic naevus patterns by age and body site in the high risk and general Queensland populationsDouglas, N. C., Borgovan, T., Carroll, M. J., Siskind, V., Wurm, E. M. T., Smithers, B. M., Green, A. C. and Soyer, H. P. (2011). Dermoscopic naevus patterns by age and body site in the high risk and general Queensland populations. MALDEN: WILEY-BLACKWELL. |
|
2011 Journal Article Is concurrent radiation therapy required in patients receiving preoperative chemotherapy for adenocarcinoma of the oesophagus? A randomised phase II trialBurmeister, Bryan H., Thomas, Janine M., Burmeister, Elizabeth A., Walpole, Euan T., Harvey, Jennifer A., Thomson, Damien B., Barbour, Andrew P., Gotley, David C. and Smithers, B. Mark (2011). Is concurrent radiation therapy required in patients receiving preoperative chemotherapy for adenocarcinoma of the oesophagus? A randomised phase II trial. European Journal of Cancer, 47 (3), 354-360. doi: 10.1016/j.ejca.2010.09.009 |
|
2011 Journal Article Factors associated with postoperative pulmonary morbidity after esophagectomy for cancerZingg, Urs, Smithers, Bernard M., Gotley, David C., Smith, Garett, Aly, Ahmad, Clough, Anthony, Esterman, Adrian J., Jamieson, Glyn G. and Watson, David I. (2011). Factors associated with postoperative pulmonary morbidity after esophagectomy for cancer. Annals of Surgical Oncology, 18 (5), 1460-1468. doi: 10.1245/s10434-010-1474-5 |
|
2011 Journal Article Dermoscopic naevus patterns in people at high versus moderate/low melanoma risk in QueenslandDouglas, Nicola C, Borgovan, Theo, Carroll, Melissa J., Williams, Patricia F., Berry, Elizabeth G., Victor Siskind, Hoedl, Andreas F., Wurm, Elisabeth M.T., Smithers, B. Mark, Green, Adele C. and Soyer, H. Peter (2011). Dermoscopic naevus patterns in people at high versus moderate/low melanoma risk in Queensland. Australasian Journal of Dermatology, 52 (4), 248-253. doi: 10.1111/j.1440-0960.2011.00798.x |
|
2011 Conference Publication A phase I, open-label, cohort study of two doses of coxsackievirus A21 given intratumorally in stage IV melanoma.Shafren, D., Smithers, B. M. and Formby, M. (2011). A phase I, open-label, cohort study of two doses of coxsackievirus A21 given intratumorally in stage IV melanoma.. 2011 ASCO Annual Meeting, Chicago, Illinois, 3-7 June 2011. Alexandria, VA, United States: American Society of Clinical Oncology. doi: 10.1200/jco.2011.29.15_suppl.8573 |
